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A NOVEL METHOD FOR ESTIMATING THE EFFECTS OF ADHERENCE 
TO ANTIHYPERTENSIVES AND DURATION OF DRUG ACTION ON 
CARDIOVASCULAR RISK
Lowy A, Brede Y
Novartis Pharma AG, Basel, Switzerland
Most patients miss occasional doses of antihypertensive treatment. The consequent 
loss of blood pressure (BP) control, and thus increased cardiovascular risk, may be 
mitigated by prescribing “forgiving” drugs that have a duration of antihypertensive 
effect beyond the 24-hour dosing interval. However, the consequences of missed doses 
for cardiovascular outcomes, and additional impact of duration of drug action, have 
not been evaluated quantitatively. We developed a method to quantify the chain of 
factors linking adherence and duration of drug action with outcomes; an important 
consideration given that adherence and hence BP reduction in real-world clinical 
practice are typically much lower than in randomised controlled trials. The method 
involves simulating 256-day dosing histories for 1250 individuals, incorporating real-
istically distributed gaps in dosing based on a study of electronically monitored dosing 
records from 4783 hypertensive patients in clinical trials. Percentage adherence is 
adjusted by altering the proportion of doses missed while preserving a realistic distri-
bution of gap length. Systolic BP (SBP) reduction for each patient is estimated, with 
rises and falls according to the individual’s dosing behaviour. By averaging SBP reduc-
tions over time and individuals, population mean SBP reduction is estimated. Cardio-
vascular disease (CVD) risk over, for example, 10 years may then be predicted using 
the Framingham Risk Equation, with baseline characteristics from NHANES 2005–
2006 (average data: age 65.2 years; 52.9% women; SBP 155.95 mmHg; total choles-
terol 5.41 mmol/L) and baseline absolute 10-year CVD risk of 27.0%. The method 
allows variable inputs including adherence level (%), rate of loss of antihypertensive 
effect when treatment is interrupted (mmHg/day), rate of BP reduction when treatment 
is (re)started (mmHg/day) and SBP-lowering effect of uninterrupted treatment 
(mmHg). In conclusion, we describe a novel method that allows quantiﬁ cation of the 
effects of treatment adherence and antihypertensive drug forgiveness on clinical out-
comes (i.e. SBP and CVD risk reduction).
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AN APPLICATION OF IMPUTATION TECHNIQUES TO IMPROVE DATA 
AVAILABILITY FROM ELECTRONIC MEDICAL RECORDS
Exuzides A, Colby C
ICON Clinical Research, San Francisco, CA, USA
OBJECTIVES: Analytic data sets based on electronic Medical Records (eMRs) offer 
long and detailed patient follow-up, large sample sizes, and a rich set of variables. 
However, the existence of a particular variable within an eMR is no assurance of 
actual data availability for all patients. Patients may receive lab tests irregularly or 
miss visits. Reporting standards can vary within an eMR system, creating large 
numbers of patients with missing data. We present details from a three step imputation 
process to improve eMR data availability from an observational study of hypertension 
outcomes. METHODS: We used an analytic data set comprised of 227,257 patients 
from 10 participating medical centers. One important element of the study was the 
computation of a cardiovascular risk score based on 11 demographic and clinical 
variables available from eMRs. However, only 43,676 patients (19%) had complete 
data for all 11 variables. To increase the sample size of patients with complete data 
for all 11 variables, we used three imputation techniques: we ﬁ rst allowed for lab and 
blood pressure values to be carried forward to replace missing values; we then aug-
mented a missing diabetes status with pharmacy data by using diabetes-speciﬁ c medi-
cations to indicate a positive diabetes history; and, ﬁ nally, we applied a multiple 
imputation (MI) technique, based on a Markov Chain Monte Carlo (MCMC) 
approach, implemented using SAS® PROC MI. RESULTS: After application of the 
three data imputation techniques, the sample size of patients with complete or imputed 
data for all 11 variables increased to 75,209 (33%). This amounts to a substantial 
increase (72%) in the number of patients with all critical variables available to be used 
for further analysis. CONCLUSIONS: Proper application of imputation techniques, 
including MI, can yield a substantial increase in the number of patients available for 
analysis. 
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A SYSTEMATIC REVIEW OF THE DIAGNOSTIC ACCURACY OF 
SEROLOGIC TESTS IN THE DIAGNOSIS OF CELIAC DISEASE
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OBJECTIVES: To evaluate the diagnostic accuracy of IgA (immunoglobulin A) and 
IgG serologic tests in the diagnosis of celiac disease including anti-tissue transgluta-
minase (tTG) antibody, anti-deamidated gliadin peptide antibody (DGP), anti-endo-
mysial antibody (EMA), and anti-gliadin antibodies (AGA). METHODS: A systematic 
review of the peer-reviewed literature was conducted to identify studies that evaluated 
the sensitivity and speciﬁ city of serologic celiac disease tests using small bowel biopsy 
as the gold standard. The patient population consisted of untreated, undiagnosed 
subjects with symptoms consistent with the disease. Pooled estimates of sensitivity and 
speciﬁ city were calculated using a bivariate, binomial generalized linear mixed model 
(SAS 9.2) which takes into account the negative correlation between sensitivity and 
speciﬁ city. Statistical signiﬁ cance was deﬁ ned by p-values less than 0.05, where “false 
discovery rate” adjustments were made for multiple hypothesis testing. RESULTS: In 
total, 17 studies were eligible for the analysis. The pooled analysis showed that IgA 
tTG has a sensitivity of 92.1% (95% CI 88.0, 96.3), compared to 89.2% (83.3, 95.1, 
p = 0.12) for IgA DGP, 85.1% (79.5, 94.4, p = 0.07) for IgA EMA, 74.9% (63.6, 
86.2, p = 0.0003) for IgA AGA. Combining more than one serologic test slightly 
increased the sensitivity, 95.1% (92.2, 98%, p = 0.039 vs. IgA tTG). The pooled 
sensitivity of IgG DGP was 88.4% (95% CI: 82.1, 94.6), 44.7% (30.3, 59.2, p = 
0.0003) for IgG tTG, and 69.1% (56.0, 82.2, p = 0.34) for IgG AGA. Speciﬁ city 
ranged from 90.1% to 93.9% and was similar among the different tests. The quality 
of the evidence according to the GRADE Working Group criteria was considered 
“moderate” for IgA tTG and EMA, “low” for IgA DGP and test combinations, and 
“very low” for IgA AGA. CONCLUSIONS: The evidence available suggests that IgA 
tTG has a higher accuracy than other serologic tests. Combining more than one 
serologic test contributes little to the diagnostic accuracy.
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OBJECTIVES: Until recently, few head-to-head trials evaluated the efﬁ cacy of pegin-
terferon-alpha-2a versus peginterferon-alpha-2b and none meta-analysis was available 
so far. In 2010, a meta-analysis performed by Awad et al was able to demonstrate 
that peginterferon-alpha-2a was more efﬁ cacious in achieving sustained virological 
response as compared to peginterferon-alpha-2b. McHutchison 2009, one of the 
studies included in the meta-analysis, evaluated two different doses of peginterferon-
alpha-2b (standard-dose: 1,5 mcg/kg; low-dose: 1,0 mcg/kg), raising doubts about 
possible negative impact of lower dose on the analysis results.We aim to compare 
treatment outcomes in genotypes 1/4 HCV infection treated with peginterferon-alpha-
2a versus peginterferon-alpha-2b at standard-dose (per package insert) both plus riba-
virin in order to assess efﬁ cacy, performing a systematic review and meta-analysis of 
published randomized controlled trials (RCTs). METHODS: An extensive search 
through main medical information databases (MEDLINE, Cochrane Library, Embase 
and Lilacs) and specialized websites was conducted on the second trimester of 2010. 
We aim to indentify RCTs which evaluate treatment efﬁ cacy of peginterferon-alpha-2a 
versus standard-dose peginterferon-alpha-2b both plus ribavirin for HCV treatment 
in genotypes 1/4 patients not co-infected with HIV. According to heterogeneity test, 
a ﬁ xed or a random-effect model was adopted. RESULTS: Only 6 papers out of 623 
found (databases citation without duplicates plus manual searches) met our inclusion 
criteria: 1)Ascione, 2009; 2)Rumi, 2009; 3)McHutchison, 2009; 4)Yenice, 2006; 5)
Scotto, 2008; 6)Berak, 2007. For genotypes 1/4 chronic HCV infection patients, 
peginterferon-alpha-2a showed higher SVR as compared to standard dose of pegin-
terferon-alpha-2b: 42.09% versus 33.44% (RR = 1.10, IC 95% 1.006–1.202, assum-
ing a ﬁ xed-effect framework). CONCLUSIONS: According to these results, no 
signiﬁ cant impact on already published meta-analysis results was observed when lower 
dose peginterferon-alpha-2b patients were excluded from the analysis. In summary, 
peginterferon-alpha-2a is more effective in treating genotypes 1/4 HCV infected 
patients as compared to standard-dose peginterferon-alpha-2b, both in association 
with ribavirin.
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POUCHITIS; A META-ANALYSIS
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OBJECTIVES: Pouchitis is the most frequent long-term complication of ileal pouch-
anal anastomosies (IPAA) surgery for ulcerative colitis (UC) which is a nonspeciﬁ c 
inﬂ ammation of the ileal reservoir. Its clinical frequency varies depending on the deﬁ ni-
tion and the follow up but is approximately 50% after a decade. Antibiotics and 
probiotics are currently the most widely accepted treatment in pouchitis patients. 
Objective of this study was to meta-analyze efﬁ cacy of probiotics and antibiotics in 
the management of pouchitis. METHODS: All databases specially Pubmed, Web of 
Science, Scopus, Cochrane, and Google Scholar were searched between 1965 and 
December 2009, and relevant controlled clinical trials were extracted, reviewed, and 
validated according to the study protocol. The outcome of interest was deﬁ ned by a 
pouchitis disease activity index (PDAI) < 7. Thirteen clinical trials were included in 
the meta-analysis. RESULTS: Pooling of the results from eight trials yielded a relative 
risk (RR) of 5.33 with a 95% CI of 2.12–13.35 and a signiﬁ cant RR (P = 0.0004) in 
the treatment group in comparison with the placebo group. Summary RR for clinical 
improvement in 6 trials was 14.17 with a 95% CI of 1.19–168.93 (P = 0.036) in 
